• hCTLA‑4 expression pattern in hCTLA-4/hLAG3 mice recapitulates mCTLA-4 in wild-type mice

  Splenocytes from hCTLA-4/hLAG3 double-homozygous mice were activated with coated αCD3/αCD28 and mIL-2 for 2 days (A, B) or indicated time (C,D). hCTLA-4 and mCTLA-4 expressions were evaluated on A) Tregs (viable, CD3⁺CD4⁺CD25⁺Foxp3⁺), B) conventional CD4⁺ (viable, CD3⁺CD4⁺Foxp3^-), and C, D) CD8⁺ (viable, CD3⁺CD8⁺) T cells.

   

  

• hLAG3 expression pattern in hCTLA‑4/hLAG3 double-humanized model

  Splenocytes from wild-type or hCTLA-4/hLAG3 double-homozygous mice were activated with coated αCD3/αCD28 and mIL-2 for 2 days (A, B) or indicated time (C, D). hLAG3 and mLAG3 expression on A) Tregs (viable, CD3⁺CD4⁺CD25⁺Foxp3⁺), B) conventional CD4⁺ (viable, CD3⁺CD4⁺Foxp3^-), and C, D) CD8⁺ (viable, CD3⁺CD8⁺) T cells.

  

Case studies

Scientific articles

1. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
2. A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway
3. An alternative approach to immunotherapy: A bispecific agonist
4. Relevant preclinical models to test T-cell engagers: The case of CD28
5. Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies
6. Part 4: Humanized immune checkpoint mouse models for immuno-oncology studies
7. A VISTA on naive T cell fate
8. A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies
9. Immune checkpoint inhibitors: A strategy to tackle cancer?

Posters

1. Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies